Zimbabwe has turned down a major American healthcare agreement valued at $367m (272 million pounds) over five years because of the United States' demand for sensitive data.
The decision became public after a government memo from December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government representative later clarified that the US was demanding access to biological samples for research and commercial gain while was unwilling to guarantee the resulting advantages from future medical innovations.
"We will now turn to the challenging and unfortunate task of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had provided over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued negotiations to find a deal acceptable to both sides so the nation's critical HIV treatment initiative can proceed.
Wider Background
This rejection comes after a comparable case in Kenya, where a court blocked a related health funding agreement following concerns were filed about the safety of citizens' health data.
After returning to office last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had administered aid for the American government, but Trump claimed its spending was "wasteful" and his government was pursuing government-to-government deals to boost transparency and accountability.
Based on reports, 16 African countries have to date agreed to similar agreements, representing more than $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership could have provided extraordinary advantages for Zimbabwean communities, particularly the 1.2 million presently on antiretroviral therapy through US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, without any corresponding promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," he stated.
"In essence, our country would provide the raw materials for scientific discovery without any certainty that the end products would be available to our people should a new disease outbreak emerge."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining systems already established through the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to deal with future global health emergencies.
"This mechanism is intended to guarantee that when a nation contributes its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to create them."
Zimbabwe's reservations over the US deal "are not meant as anti-American sentiment," he added.
"We welcome ongoing discussions with our American counterparts on how future co-operation might be structured in a manner that respects the sovereignty and dignity of both nations."
Health Experts Reaction
Medical experts said it acknowledged the government's concerns, but suggested that negotiations should continue since a large portion of the nation's HIV programmes relied on foreign aid.
"In cases where specific concerns arise, such as those involving information security or agreement terms, these can often be addressed through detailed discussion and mutually agreed protections," it said.
The halted deal emphasises the continuing debate between accepting much-needed international aid and safeguarding local interests in an increasingly data-driven world.